Demonstrates enhanced antitumor efficacy in hepatocellular carcinoma with combination treatment, suggesting a novel therapeutic approach.
BACKGROUND: Molecular targeted therapies play a crucial role in the management of hepatocellular carcinoma (HCC). Lenvatinib is a standard targeted agent for advanced HCC, while quercetin has emerged as a promising natural compound with anti-HCC potential. This study investigates the combined effect of quercetin and lenvatinib on HCC. METHODS: experiments were conducted to validate the anti-tumor efficacy of the combination treatment. CONCLUSION: Quercetin significantly enhances the anti-tumor efficacy of lenvatinib, likely through synergistic inhibition of PTK2 expression.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: